As On: 03 Aug 2026
| Arvind Ltd
|
Arvind Limited has received approval from its Finance Committee to launch a qualified institutions placement (QIP) of equity shares with a floor price of Rs 518.58 per share, according to a regulatory filing on August 3, 2026. The QIP is being conducted under Chapter VI of the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018, and Sections 42 and 62 of the Companies Act, 2013, and may include a discount of up to 5% on the floor price at the company’s discretion. |
| Ashok Leyland
|
Ashok Leyland Limited will hold a board meeting on August 14, 2026, to consider and approve the standalone and consolidated unaudited financial results for the quarter ended June 30, 2026, according to a regulatory filing. The trading window for designated persons and their immediate relatives has been closed since July 1, 2026, and will remain so until 48 hours after the unaudited financial results are made public. |
| Bombay Dyeing
|
The Bombay Dyeing and Manufacturing Company Limited will hold a board meeting on Monday, August 10, 2026, to consider and approve the unaudited financial results for the first quarter ended June 30, 2026, according to a regulatory filing with the BSE Ltd and National Stock Exchange of India Ltd. |
| Escorts Kubota
|
Escorts Kubota Limited stated there was no deviation or variation in the use of proceeds from its preferential issue of Rs 1,872.745 crore raised on February 18, 2022, according to a filing with the BSE Limited and National Stock Exchange of India Limited on August 3, 2026. The company’s Audit Committee reviewed the statement, which was filed pursuant to Regulation 32 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. |
| Glaxosmi. Pharma
|
GlaxoSmithKline Pharmaceuticals Ltd (GSK India) announced a 15% year-over-year increase in revenue to INR 924 crores for the first quarter ended June 30, 2026, with Profit After Tax (PAT) rising 24% to INR 253 crores, according to a press release issued Tuesday. The company’s performance reflects continued progress in its portfolio transformation strategy, with key promoted brands like Augmentin and Zejula demonstrating strong growth, and the Oncology business led by Jemperli and Zejula significantly expanding patient reach, while GSK India is preparing for key pipeline launches including Blenrep and Arexvy. |